This clinical trial is focused on studying a type of cancer called Esophageal Squamous Cell Carcinoma, which affects the esophagus, the tube that carries food from the mouth to the stomach. The study is specifically for patients with locally advanced cases of this cancer that cannot be removed by surgery. The main treatment being tested is a medication called Durvalumab, also known by its code name MEDI4736. Durvalumab is given alongside a standard treatment called chemoradiation therapy, which combines chemotherapy and radiation therapy to treat cancer. The study will compare the effects of Durvalumab with a placebo, which looks like the real treatment but does not contain any active medication.

The purpose of the study is to see how well Durvalumab works when used with chemoradiation therapy in treating this type of cancer. Participants in the study will receive either Durvalumab or a placebo, along with chemoradiation therapy. The study will monitor the participants over a period to observe the effects of the treatment on their cancer. The study will also collect information on how the treatment affects the participants’ quality of life and any side effects they may experience.

Other medications involved in the study include Fluorouracil, Cisplatin, and Capecitabine, which are types of chemotherapy drugs, as well as Infliximab and Mycophenolate Mofetil, which are used to manage immune responses. These medications are administered in different forms, such as injections, infusions, or tablets, depending on the specific treatment plan. The study aims to provide valuable information on the effectiveness and safety of using Durvalumab in combination with these treatments for patients with this type of esophageal cancer.